MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Portfolio Pulse from
MIRA Pharmaceuticals has successfully completed its preclinical safety program for Ketamir-2, a novel oral ketamine analog, with no adverse findings. This achievement paves the way for the submission of an Investigational New Drug (IND) application by the end of 2024.
December 10, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals has validated the safety of Ketamir-2, a novel ketamine analog, with no adverse findings in preclinical studies. This milestone supports the upcoming IND submission, potentially advancing the company's clinical trials in neuropathic pain.
The successful completion of the preclinical safety program without adverse findings is a significant milestone for MIRA Pharmaceuticals. It indicates progress towards clinical trials, which could enhance investor confidence and positively impact the stock price. The news is highly relevant and important as it directly affects the company's future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100